These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11726029)

  • 1. Enhancing cytotoxic T cell responses with altered-peptide ligands.
    Zhao R; Collins EJ
    Arch Immunol Ther Exp (Warsz); 2001; 49(4):271-7. PubMed ID: 11726029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural implications for the design of molecular vaccines.
    Apostolopoulos V; Yu M; McKenzie IF; Wilson IA
    Curr Opin Mol Ther; 2000 Feb; 2(1):29-36. PubMed ID: 11249650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the activity of partially agonistic MHC:peptide ligands dependent on the quality of immunological help?
    Uhlin M; Masucci M; Levitsky V
    Scand J Immunol; 2006 Dec; 64(6):581-7. PubMed ID: 17083613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of peptide interaction with MHC creates TCR partial agonists.
    Ryan KR; McNeil LK; Dao C; Jensen PE; Evavold BD
    Cell Immunol; 2004 Jan; 227(1):70-8. PubMed ID: 15051516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide binding by class I and class II MHC molecules.
    Batalia MA; Collins EJ
    Biopolymers; 1997; 43(4):281-302. PubMed ID: 9316393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-canonical anchor motif peptides bound to MHC class I induce cellular responses.
    Lazoura E; Lodding J; Farrugia W; Day S; Ramsland PA; Apostolopoulos V
    Mol Immunol; 2009 Mar; 46(6):1171-8. PubMed ID: 19118903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. pH dependence of MHC class I-restricted peptide presentation.
    Stryhn A; Pedersen LO; Romme T; Olsen AC; Nissen MH; Thorpe CJ; Buus S
    J Immunol; 1996 Jun; 156(11):4191-7. PubMed ID: 8666787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition.
    Burrows JM; Bell MJ; Brennan R; Miles JJ; Khanna R; Burrows SR
    Mol Immunol; 2008 Mar; 45(6):1818-24. PubMed ID: 17981331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide affinity for MHC influences the phenotype of CD8(+) T cells primed in vivo.
    Ma H; Kapp JA
    Cell Immunol; 2001 Nov; 214(1):89-96. PubMed ID: 11902833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope.
    Qiu F; Cui Z
    J Immunother; 2007; 30(2):180-9. PubMed ID: 17471165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of CD8 and TCR binding to Class I MHC ligands following T cell activation.
    Kao C; Daniels MA; Jameson SC
    Int Immunol; 2005 Dec; 17(12):1607-17. PubMed ID: 16263755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and use of conditional MHC class I ligands.
    Toebes M; Coccoris M; Bins A; Rodenko B; Gomez R; Nieuwkoop NJ; van de Kasteele W; Rimmelzwaan GF; Haanen JB; Ovaa H; Schumacher TN
    Nat Med; 2006 Feb; 12(2):246-51. PubMed ID: 16462803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-induced changes in class I heavy chains alter allorecognition.
    Bluestone JA; Kaliyaperumal A; Jameson S; Miller S; Dick R
    J Immunol; 1993 Oct; 151(8):3943-53. PubMed ID: 8409378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
    Douat-Casassus C; Marchand-Geneste N; Diez E; Gervois N; Jotereau F; Quideau S
    J Med Chem; 2007 Apr; 50(7):1598-609. PubMed ID: 17328535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
    Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
    J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
    van Stipdonk MJ; Badia-Martinez D; Sluijter M; Offringa R; van Hall T; Achour A
    Cancer Res; 2009 Oct; 69(19):7784-92. PubMed ID: 19789338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class I major histocompatibility complexes loaded by a periodate trigger.
    Rodenko B; Toebes M; Celie PH; Perrakis A; Schumacher TN; Ovaa H
    J Am Chem Soc; 2009 Sep; 131(34):12305-13. PubMed ID: 19655751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.